Ed Schoonveld

Amid COVID-19, pressure for “socially responsible” pricing could temper investments in future urgent healthcare needs.

Providing evidence for a strong value proposition to each of the access journey decision makers needs to be weighed against the risk of clinical trial failure, cost of investment, and launch timing. Ed Schoonveld outlines how a pharma company can analyze and rejuvenate its decision process.

This article discusses how cost differences with other countries reflect income differences, how these differences are typical for cost in medical services, and more.

Ed Schoonveld reviews the key topics discussed at the World Health Organization's second Fair Pricing Forum, held in Johannesburg, South Africa last month.

We desperately need new anti-infective drugs to avoid life threatening infections. Let’s make that happen by punishing companies who don’t invest in R&D for these specific drugs.

The American College of Physicians chimed in on the debate surrounding prescription drug costs, offering its views for stemming the escalation. Ed Schoonveld offers a deep dive into the positions taken.